Roche Halts Emugrobart Obesity Trial After Failed Interim Analysis

Key points

• Roche stopped the phase 2 Gyminda trial for emugrobart after an interim analysis showed the drug was unlikely to succeed in its obesity indication.
• The antibody was designed to block myostatin to help patients retain muscle mass while using GLP-1 agonists like tirzepatide for weight loss.
• Roche has returned emugrobart to Chugai, which will resume development for spinal muscular atrophy (SMA) and explore out-licensing opportunities.
• Emugrobart previously failed to show consistent muscle growth improvements in trials for SMA and facioscapulohumeral muscular dystrophy in March 2026.
• Chugai cited the drug's safety profile and dosing data as reasons to support a potential phase 3 study in SMA despite the obesity trial failure.

Background

This development is part of Roche's broader strategy to compete in the obesity market, where muscle loss is a significant side effect of current GLP-1 drugs. In August 2026, Roche licensed HM17321 from Hanmi for up to $2.3 billion to address muscle preservation. Additionally, Roche recently reported that its dual agonist enicepatide showed superior diabetes control compared to competitors, reinforcing its push to become a top-three player in the obesity space despite the emugrobart setback.

How outlets are covering it

Fierce Biotech provides detailed context on the interim analysis failure and the specific handover to Chugai, noting the previous failures in muscular dystrophy trials. Endpoints News confirms the cancellation of the muscle-preserving obesity drug but offers limited detail due to paywall restrictions. FirstWord was inaccessible due to a JavaScript loading error, providing no additional perspective. All available sources agree on the termination of the obesity trial and the return of the asset to Chugai, with Fierce Biotech offering the most comprehensive explanation of the rationale behind Chugai's continued interest in SMA.

Why it matters

The failure of emugrobart highlights the difficulty in developing drugs that simultaneously promote weight loss and preserve muscle, a key unmet need in the obesity market. While Roche loses a candidate, the move allows Chugai to focus on rare genetic diseases, and Roche can continue pursuing other assets like enicepatide and HM17321 to maintain its competitive position against Lilly and Novo Nordisk.

What to watch

Chugai will prepare for a potential phase 3 study of emugrobart in spinal muscular atrophy and seek third-party licensing partners. Roche will continue advancing its other obesity candidates, including enicepatide and the newly licensed HM17321, to address muscle preservation and weight loss in its cardiometabolic portfolio.